Form 4: Brainstorm Cell Therapeutics Executive Acquires Shares Through Stock Award

Ibrahim B. Dagher, Chief Medical Officer of Brainstorm Cell Therapeutics, acquired 50,000 shares of restricted stock on January 1, 2025, under the company's 2014 Global Share Option Plan.

Summary

• On January 1, 2025, Ibrahim B. Dagher, the Chief Medical Officer of Brainstorm Cell Therapeutics, acquired 50,000 shares of common stock.
• These shares were awarded as restricted stock under the Issuer's 2014 Global Share Option Plan.
• 50% of the award will vest on the six-month anniversary of the grant date, and the remaining 50% will vest on the eighteen-month anniversary, contingent upon continued employment.
• The reporting person also has 10,666 shares held in a Roth IRA and 2,000 shares held in a custodial account for a child.
• These share amounts reflect a 1-for-15 reverse stock split that took place on October 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock ownership changes by an executive. The stock award could be seen as a positive, but it's a standard part of executive compensation.

Positives

• The acquisition of shares by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock is contingent upon the Reporting Person's continued employment with the Issuer.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. Monitoring these filings can offer insights into management's sentiment and potential future performance of the company.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Ibrahim B. Dagher, restricted stock, stock award, Form 4, insider trading, Chief Medical Officer, reverse stock split